Hi, we've made some changes

ValiRx(VAL)

Sector:

Pharmaceuticals & Biotechnology

Index:

FTSE AIM All-Share

Market Cap

£2.91m

Change Today

Price Down-0.50p

Share Price

6.25p

ValiRx jumps on EU patent approval

Date: Wednesday 08 Aug 2007

LONDON (ShareCast) - Shares in cancer therapeutics company ValiRx rallied on news that the European patent office has approved its proprietary gene-silencing technology GeneICE for 23 European states.

The initial results from CRT's pre-clinical trials are expected in September.

The group said it holds the rights to GeneICE through its subsidiary Cronos Therapeutics, which has an exclusive worldwide license agreement with Imperial College Innovations.

"We are delighted to have received this European patent which makes the technology securely protected in the world's major life science markets: the US and Europe," Satu Vainikka, chief executive commented.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

ValiRx Market Data

Currency UK Pounds
Share Price 6.25p Price Down
Change Today -0.50p
52 Week High 23.25p
52 Week Low 6.25p
Volume 2,633
Shares Issued 46.50m
Market Cap £2.91m
Beta 0.30
RiskGrade 227

Performance Indicators

Compare performance with the sector and the market.
Find out more
Key: vs Market vs Sector
Value
12.54% below the market average12.54% below the market average12.54% below the market average12.54% below the market average12.54% below the market average
8.43% above the sector average8.43% above the sector average8.43% above the sector average8.43% above the sector average8.43% above the sector average
Price Trend
67.13% below the market average67.13% below the market average67.13% below the market average67.13% below the market average67.13% below the market average
47.25% below the sector average47.25% below the sector average47.25% below the sector average47.25% below the sector average47.25% below the sector average
Income Not Available
Growth
29.24% below the market average29.24% below the market average29.24% below the market average29.24% below the market average29.24% below the market average
44% below the sector average44% below the sector average44% below the sector average44% below the sector average44% below the sector average
Price Chg 6m
66.75% below the market average66.75% below the market average66.75% below the market average66.75% below the market average66.75% below the market average
60.44% below the sector average60.44% below the sector average60.44% below the sector average60.44% below the sector average60.44% below the sector average
P/E Not Available
PEG Not Available
Dividend Yield Not Available
EPS Growth Not Available
Operating Margin
95.27% below the market average95.27% below the market average95.27% below the market average95.27% below the market average95.27% below the market average
50.65% below the sector average50.65% below the sector average50.65% below the sector average50.65% below the sector average50.65% below the sector average

ValiRx Dividends

No dividends found

Trades for --2008

Time Volume / Share Price
0 @ 0.000p

Digital Look have been voted
"Best Research and Information Provider"

4th Floor, Bankside House, 107 Leadenhall Street, London EC3A 4AF.
Registered in England and Wales (registered no. 3678570).